Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215 , in adults with overweight or obesity: Results from a phase 1 randomized clinical trial
Authors' conclusion
An adaptive continuous infusion of the GLP-1/GCGR co-agonist, G3215, is safe and well tolerated offering a unique strategy to control drug exposure. By allowing rapid, response-directed titration, this strategy may allow for mitigation of adverse effects and afford significant weight loss within shorter time horizons than is presently possible with weekly GLP-1R and multi-agonists. These results support ongoing development of G3215 for the treatment of obesity and metabolic disease.
Study context
- Population
- Adults with overweight or obesity, with or without T2D23 completed
- Participants
- 26 adults
- Comparison
- 14-day continuous SC infusion of glucagon-like peptide receptor (GLP-1R)/GCGR co-agonist G3215 vs placebo
- Primary endpoint
- Safety and tolerability of continuous infusion of G3215
Methodological detailsphase 1, double-blind, placebo-controlled
- Phase 1
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Safety and tolerability · 14 days
- Most common AEs were nausea or vomiting, mild in most cases and mitigated by real-time adjustment of drug infusion
- No cardiovascular concerns with G3215 infusion
Further findings
Body weight loss · 14 days
P < 0.05
Pharmacokinetics
- PK characteristics in keeping with continuous infusion over 14 days
Food consumption, glycaemia, lipids and amino acids
- Reduced food consumption with G3215; no deterioration in glycaemia
- Improved lipid profile with G3215
- Broad reduction in circulating amino acids during infusion, consistent with GCGR activation
Original publication
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215 , in adults with overweight or obesity: Results from a phase 1 randomized clinical trial. Diabetes Obes Metab. Published 16 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →